Taiwan
· Delayed Price · Currency is TWD Intech Biopharm Statistics
Total Valuation
Intech Biopharm has a market cap or net worth of TWD 3.75 billion. The enterprise value is 4.86 billion.
| Market Cap | 3.75B |
| Enterprise Value | 4.86B |
Important Dates
The last earnings date was Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Intech Biopharm has 137.94 million shares outstanding. The number of shares has increased by 16.14% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 137.94M |
| Shares Change (YoY) | +16.14% |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | 1.28% |
| Owned by Institutions (%) | 1.92% |
| Float | 74.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 108.30 |
| PB Ratio | 4.10 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -13.42 |
| EV / Sales | 142.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -15.12 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 1.58.
| Current Ratio | 1.31 |
| Quick Ratio | 0.95 |
| Debt / Equity | 1.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.47 |
| Interest Coverage | -10.13 |
Financial Efficiency
Return on equity (ROE) is -42.40% and return on invested capital (ROIC) is -9.28%.
| Return on Equity (ROE) | -42.40% |
| Return on Assets (ROA) | -8.84% |
| Return on Capital (ROIC) | -9.28% |
| Revenue Per Employee | 415,512 |
| Profits Per Employee | -4.41M |
| Employee Count | 82 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 4.12 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.09% in the last 52 weeks. The beta is 0.32, so Intech Biopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +2.09% |
| 50-Day Moving Average | 28.78 |
| 200-Day Moving Average | 28.56 |
| Relative Strength Index (RSI) | 33.29 |
| Average Volume (20 Days) | 69,212 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Intech Biopharm had revenue of TWD 34.07 million and -361.71 million in losses. Loss per share was -2.67.
| Revenue | 34.07M |
| Gross Profit | -160.51M |
| Operating Income | -345.97M |
| Pretax Income | -361.71M |
| Net Income | -361.71M |
| EBITDA | -259.52M |
| EBIT | -345.97M |
| Loss Per Share | -2.67 |
Balance Sheet
The company has 333.98 million in cash and 1.44 billion in debt, giving a net cash position of -1.10 billion or -8.00 per share.
| Cash & Cash Equivalents | 333.98M |
| Total Debt | 1.44B |
| Net Cash | -1.10B |
| Net Cash Per Share | -8.00 |
| Equity (Book Value) | 908.82M |
| Book Value Per Share | 6.63 |
| Working Capital | 112.55M |
Cash Flow
In the last 12 months, operating cash flow was -276.95 million and capital expenditures -44.22 million, giving a free cash flow of -321.17 million.
| Operating Cash Flow | -276.95M |
| Capital Expenditures | -44.22M |
| Free Cash Flow | -321.17M |
| FCF Per Share | -2.33 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,015.40% |
| Pretax Margin | -1,061.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -942.63% |
Dividends & Yields
Intech Biopharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.14% |
| Shareholder Yield | -16.14% |
| Earnings Yield | -9.82% |
| FCF Yield | -8.56% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |